论文部分内容阅读
Following concurrent radio-chemotherapy or first-line chemotherapy for advanced non-small cell lung cancer (NSCLC),continuous maintenance therapy given to patients with stable disease(SD)and follow-up treatment is called consolidation therapy.Concerning NSCLC patients with a non-operable dry Stage-IIIB(N3)disease,i.e.contra-lateral mediastinal and hilar lymph node,or homolateral/contra-lateral scalene and Troisier sign,a 2 or 3-course of standard-dosage Taxotere consolidation therapy can be performed a er concurrent radio-chemotherapy.In pursuance of evidence-based medicine(EBM),low-dose Taxotere maintenance therapy,and biological targeted therapy of patients with appropriate symptoms are suitable for second-line therapy for moist of the Stage-IIIB(malignant pleural effusion)and IV patients.
Following concurrent radio-chemotherapy or first-line chemotherapy for advanced non-small cell lung cancer (NSCLC), continuous maintenance therapy given to patients with stable disease (SD) and follow-up treatment is called consolidation therapy. Concerning NSCLC patients with a non -operable dry Stage-IIIB (N3) disease, iecontra-lateral mediastinal and hilar lymph node, or homolateral / contra-lateral scalene and Troisier sign, a 2 or 3-course of standard-dosage Taxotere consolidation therapy can be performed a er concurrent radio-chemotherapy in pursuance of evidence-based medicine (EBM), low-dose Taxotere maintenance therapy, and biological targeted therapy of patients with appropriate symptoms are suitable for second-line therapy for moist of the Stage-IIIB (malignant pleural effusion ) and IV patients.